Amadou A. Sall
Institut Pasteur de Dakar, Senegal
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amadou A. Sall as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:35 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04390594 · Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in SenegalInstitut Pasteur de Dakar · terminated · COVID-19 · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:35 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.N Engl J Med · 2016382 citationsRCR 13.1
- Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.Lancet Infect Dis · 202314 citationsRCR 1.6
- Low-Dose Yellow Fever Vaccine in Adults in Africa.N Engl J Med · 202512 citationsRCR 3.4
- A multi-country phase 2 study to evaluate the suitcase lab for rapid detection of SARS-CoV-2 in seven Sub-Saharan African countries: Lessons from the field.J Clin Virol · 20235 citationsRCR 0.8
- Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial.Lancet · 20265 citationsRCR 2.5